Samsung electronics is diversifying into bio pharmaceuticals, South Korea’s largest conglomerate is going for joint venture with investment of around $264.4 million, this is a new venture for the firm, for this new venture the tech giant will partner with Quintile’s world's leading clinical research organization which has good experience in biopharmaceutical development, with this JV Samsung tends to produce bio therapeutics for treatment of cancer and arthritis.
Already there are some players which are operating in Biosimilar region from Korea, LG Electronics one of the competitor for Samsung went ahead many years back for biosimilar venture and have been very active since then India, China, Korea and South east Asia, There is still lot to happen in the APAC region in the biosimilar domain, though entry barrier is there, but outsourcing of some processes from the value chain is making it a effective domain for investment.
Already there are some players which are operating in Biosimilar region from Korea, LG Electronics one of the competitor for Samsung went ahead many years back for biosimilar venture and have been very active since then India, China, Korea and South east Asia, There is still lot to happen in the APAC region in the biosimilar domain, though entry barrier is there, but outsourcing of some processes from the value chain is making it a effective domain for investment.
For Samsung JV- Source: http://ca.reuters.com/article/technologyNews/idCATRE71O0F020110225
